chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Other vaccine same date product: Pfizer; dose number: 3; Other vaccine same date product: Moderna; dose number: 4; Raised, hard, warm red welt about 2 inches in diameter. Painful when touched; Raised, hard, warm red welt about 2 inches in diameter. Painful when touched; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An adult female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 30Sep2023 at 12:30 as dose 6 (booster), single (Lot number: HD9876) intramuscular, in left arm for covid-19 immunisation; influenza vaccine inact sag 3v (FLUCELVAX), on 30Sep2023 as dose 1, single (Lot number: 944484), in right arm. The patient's relevant medical history included: "known allergies: Yes" (unspecified if ongoing), notes: Name of Drug as Reported: Yes, Reaction: Allergy. Concomitant medication(s) included: SHINGRIX, on 10Sep2023 as dose 1, single. Vaccination history included: Bnt162b2;bnt162b2 omi ba.4-5 (Proprietary medicinal product name: Pfizer, Dose: 05, Batch/lot number: GH9703, Anatomical Location: Arm left, Date of start of drug: 30Sep2023), for COVID-19 Immunization; Moderna covid-19 vaccine (Proprietary medicinal product name: Moderna, Dose: 04, Batch/lot number: 066K21A   , Anatomical Location: Arm left, Date of start of drug: 30Sep2023), for COVID-19 Immunization; Bnt162b2 (Proprietary medicinal product name: Pfizer, Dose: 03, Batch/lot number: FF8841, Anatomical Location: Arm left, Date of start of drug: 30Sep2023), for COVID-19 Immunization; Bnt162b2 (Proprietary medicinal product name: Pfizer, Dose: 02, Batch/lot number: EW0102, Anatomical Location: Arm left, Date of start of drug: 30Sep2023), for COVID-19 Immunization; Bnt162b2 (Proprietary medicinal product name: Pfizer, Dose: 01, Batch/lot number: EPP6955, Anatomical Location: Arm left, Date of start of drug: 30Sep2023), for COVID-19 Immunization. The following information was reported: URTICARIA (non-serious), PAIN (non-serious) all with onset 01Oct2023 at 10:00, outcome "recovering" and all described as "Raised, hard, warm red welt about 2 inches in diameter. Painful when touched"; INTERCHANGE OF VACCINE PRODUCTS (non-serious), outcome "unknown", described as "Other vaccine same date product: Pfizer; dose number: 3; Other vaccine same date product: Moderna; dose number: 4". Therapeutic measures were not taken as a result of urticaria, pain.
Injection site swelling, burning and hard raised lump for 2 weeks that darkened on second week. Hives down left arm and left chest within 24 hours. Fever of 101.2°F for 72 hours post injection. Joint swelling and pain, especially on left-side of body. Vomiting and diarrhea for 72 hours post injection. Extreme fatigue for 1 week post injection.
Oxygen saturation low/ checked his oxygen level and it was 78 and then after a few minutes it was 86 and 88; Fever of 102 F for 4 days; This is a spontaneous report from a contactable consumer (patient). A 35-year-old male patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL1283), via an unspecified route of administration (Unknown if  given intramuscularly) on 15Jan2021 09:30 at a single dose on left arm below shoulder for COVID-19 immunization. Medical history included none. There were no concomitant medications. The patient experienced fever of 102 for 4 days on 16Jan2021 14:00 and oxygen saturation low on 20Jan2021 12:00 (reported as "12:00 - 12:30"). He received first dose 15Jan2021. He has not had a cough, but had 102 degree Fahrenheit fever for 4 days, so he had to stay home from work. He  had to get a COVID test and it was negative today (unspecified date). While he was there, they checked his oxygen level and it was 78 and then after a few minutes it was 86 and 88. There was no prescriber. He received it at a healthcare facility. He is supposed to go back to get second dose on 05Feb2021. It is unknown if it was given intramuscularly. The outcome of the events was not recovered. NO ER or physician's office required.  He is to follow up with his general practitioner, but he has not gone yet. No prior vaccinations (within 4 weeks) and no adverse event following prior vaccinations. No additional vaccines administered on same date of the Pfizer Suspect. Vaccination facility type was Hospital. Family medical history includes, Father is Diabetic and mother has colon cancer.
Dizziness; High Blood sugar; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness) and BLOOD GLUCOSE INCREASED (High Blood sugar) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Apr-2021, the patient experienced DIZZINESS (Dizziness) and BLOOD GLUCOSE INCREASED (High Blood sugar). At the time of the report, DIZZINESS (Dizziness) and BLOOD GLUCOSE INCREASED (High Blood sugar) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. The patient took insulin for the high blood sugar.
feeling a little dizzy; couldn't breath; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age (Age: 72, Unit: Unknown) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number and expiry date was not reported), dose 1 via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The first dose of the Pfizer-BioNtech Covid-19 vaccine on Saturday at 5 o'clock, 20 minutes later she started feeling a little dizzy and that she couldn't breathe further she describes these symptoms as slight, and they didn't escalate. She is scared about what may happen after the second dose of the vaccine, which is scheduled on 27Feb2021. Reporter also said that some people after the first dose of the vaccine only had a sore arm. She also takes blood pressure pills in the morning. Patient questions if she would like to know if this is related to the side effects that she experienced. Also, if she can receive the Moderna vaccine for the second dose. The outcome of the events was unknown.  Information on the lot/batch number has been requested.  Follow-up attempts are completed. No further information is expected.
Allergic reaction to the first dose of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Allergic reaction to the first dose of the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERSENSITIVITY (Allergic reaction to the first dose of the vaccine). At the time of the report, HYPERSENSITIVITY (Allergic reaction to the first dose of the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator o No treatment medications provided by the reporter.
Redness to injection site on 9/7/02 with swelling then increased redness 9/5/02 with swelling and itching.
Patient received 2 doses of the Astra Zeneca vaccine then received 1 dose of the Moderna vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Patient received 2 doses of the Astra Zeneca vaccine then received 1 dose of the Moderna vaccine) in a 37-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051C21A) for COVID-19 vaccination.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD (CHADOX1 NCOV-19) (COVID-19 VACCINE ASTRAZENECA) for COVID-19 vaccination.    No Medical History information was reported.   On 07-Jun-2021, the patient received second dose of COVID-19 VACCINE NRVV AD (CHADOX1 NCOV-19) (COVID-19 VACCINE ASTRAZENECA) (unknown route) dosage was changed to 1 dosage form. On 10-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient received first dose of COVID-19 VACCINE NRVV AD (CHADOX1 NCOV-19) (COVID-19 VACCINE ASTRAZENECA) (unknown route) 1 dosage form. On 10-Jul-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Patient received 2 doses of the Astra Zeneca vaccine then received 1 dose of the Moderna vaccine). On 10-Jul-2021, INTERCHANGE OF VACCINE PRODUCTS (Patient received 2 doses of the Astra Zeneca vaccine then received 1 dose of the Moderna vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were provided by the reporter.
TIGHTNESS IN THROAT, WHEEZING, HEART PALPITATIONS, ITCHY EYES.
Patient pregnant, received live H1N1 vaccine.  11/23/09 MR from PCP for DOS 11/18/09: Vaccine exposure during pregnancy.   11/24/09 MR record from OB for DOS 10/27/09: OB exam: normal.
After injection approx 10 min, large hard knot appeared on arm, no discoloration, no pain, warm to touch, no drainage. Pt. denied N.V, fever/chills, SOB. Pt. inst. to use cool packs at site, elevate arm, take TYLENOL. Go to E.R. if symptoms worsen.
Patient states that within 24 hours after receiving vaccination, she began to experience arm pain that resulted in limited mobility and that progressed to very little use of the left arm, and pain that radiated up the left side of the neck.
Pt. had redness, swelling in right upper arm. Vaccine given in (R) deltoid. No fever or pain. Advised cold compresses today and warm compresses tomorrow.
I started to received symptoms after the 2nd vaccination. I experienced  severe gout and pain in feet (bilateral), felt as if I had the flu.   I also experienced arm pain (left).
Confusion, Sedation, Myalgia, Fever, 01/21/2021 Patient, complaining of Body aches, Chills,  Foggy brain, insomnia, concentration issues, "reaction timing  off".   Narrative:
This spontaneous report as received from a physician refers to a patient of unknown demographics. No information about medical history, drug reactions and allergies was specified. The physician reported that on an unknown date in June 2014 an unspecified patient received the 1st dose of ROTATEQ vial (lot#, dose not reported) as well as PREVNAR and PENTACEL "about 2 months ago". No concomitant medications were reported. The unspecified patient then developed severe diarrhea that lasted "about 2 weeks". There was no product quality complaint. The action taken, outcome and causality is unknown. Additional information has been requested.
Patient called Saturday October 31, at 3:15 pm. She received the vaccine around 10:15 am on Friday October 30. 2015 and at 4pm she stated she had a seizure. She did not go to the hospital. On Saturday she said she was feeling better.
Transient symptomatic Sinus tachycardia and hypertension, abrupt onset
Hospitalization for symptoms of COVID-19 on dates 7/30/2022-8/3/2022.  Treated with vitamin C 1,000 mg PO daily, vitamin D 25 mcg PO daily, zinc 50 mg PO daily.
This spontaneous report as received from registered nurse refers to a patient of unknown age and gender. Patient's concurrent conditions and relevant medical history was not reported. On 29 -SEP-2014, patient was vaccinated expired dose of ZOSTAVAX (lot number: J006827 with expiry date of 14-SEP-2014 (dose unspecified), subcutaneously. Concomitant medications were not reported. No know adverse effects were reported. The outcome of the events was unknown. This causality of the events with ZOSTAVAX was not reported. Product quality issue was not involved. Additional information has been requested.
Had positive covid-19 test on 02/03/2021 via Rapid Abbott BinaxNOW Ag card. Patient denied any symptoms.
Patient presented to the ED on 3/14/21 with anxiety. Patient presented to the ED and was subsequently admitted on 4/6/21.
2 3/4" large, red, raised area, warm to the touch. Mother gave Tylenol. This was on the left thigh.
Headache and nausea with in 10 minutes, eye burning and headache similar to whiplash within 1 hour.
She developed swollen lymph nodes in her neck about a week later and still is swollen; This is a spontaneous report received from a contactable consumer (patient). This 38-year-old female patient received dose 1 of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) via an unspecified route of administration on 09Mar2021 as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. In Mar2021, the patient developed swollen lymph nodes in her neck about a week after receiving BNT162B2 and was still swollen. The outcome of swollen lymph nodes was not recovered.   Information on lot/batch number has been requested.  Follow-up attempts are completed. No further information is expected.
Patient received tdap vaccine 1-6-23 from the hospital and also received it 1-26-23 along with covid and flu shots.  Patient stated that she didn't have any adverse reactions.
7 days after the injection the area around the vaccination site become very hot/red and itchy.  It lasted 3-4 days. Applied hydrocortisone to injection site and area surrounding to relieve the itch several times per day.
On the 19 had a horrible headache and then at about the 24 hour mark I had really bad left ear pain almost like an ear infection but worse this lasted about 24 hrs then I felt like crap for 2 more days
Pt received Covid 19 vaccination on 02/01/2021-SX on 02/16/2021-Positive for COVID 19 on 02/18/2021
Swelling of the upper limb; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Swelling of the upper limb) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Jan-2021, the patient experienced PERIPHERAL SWELLING (Swelling of the upper limb). At the time of the report, PERIPHERAL SWELLING (Swelling of the upper limb) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.  Case comment: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
?Brainstem Encephalitis?  Patient admitted to inpatient on 05/16/2021. Presented to the ED with dizziness, nausea, general fatigue and diplopia.  Patient also voiced an intermittent mild headache.  Patient was evaluated at an Urgent Care on 5/14/2021 with a ?presumed viral type illness?. In the ED, the patient denied neck pain, photophobia, eye pain, one sided weakness/numbness, facial droop, cough, congestion, and SOB.  Temperature max at home was 100.8F.  The patient does have gaze deficit and nystagmus on exam.  Negative toxicology screen. Negative SARS-COV-2 Antigen. ALT 86. Medical history includes: hypertension, depression, Vitamin D deficiency. Neurology- This is a 56-year-old patient referred to Neurology secondary to diplopia.  The patient states that her symptoms started with generalized fatigue and "not feeling well".  After 2 to 3 days [last Thursday 5/13/2021] she began having difficulty with double vision.  She has double vision in multiple directions.  The double vision is fairly constant.  Along with the double vision she feels off balance to the point where she has difficulty with walking.  She does admit to internal vertigo.  Patient denies any recent viral infections.  She is about 4 weeks out from her last COVID-19 vaccination which was Moderna.   During the hospitalization the patient has developed urinary retention requiring a foley catheter.  Hospital medications include IV Solu-medrol and subcutaneous heparin.  Patient seen by internal medicine, neurology, infectious disease, and urology during hospital stay.  The patient was discharged on 22MAY2021 after demonstrating ability to ambulate. Will continue with physical therapy outpatient.   See Tests and Lab Results Below
This case was reported by a healthcare professional and described the occurrence of hepatitis b surface antigen positive in a 27-year-old female subject who was vaccinated with ENGERIX B (GlaxoSmithKline).  On 10 June 2008, the subject received the 1st dose of ENGERIX B (unknown, left arm).  At an unspecified time after vaccination with ENGERIX B, blood work was drawn, and the subject was found to be hepatitis b surface antigen positive.  On 11 June 2008, the subject donated plasma.  a plasma donation center reported a hepatitis b surface antigen in the subject's donated plasma.  The reporting nurse was unsure if the test results were reported in June or July of 2008.  The vaccination subject told the nurse about the test results when she visited the clinic for her 2nd ENGERIX B dose in July 2008.  The subject was administered the 2nd dose of ENGERIX B on an unspecified date.  At the time of reporting, the event was unresolved.  The healthcare professional considered the event to be related to vaccination with ENGERIX B, but indicated that the event was not serious.
STERILE WATER FOR INJECTION WAS MIXED IN AS DILUENT. NO KNOWN ADVERSE REACTION REPORTED BACK TO PHARMACY YET AT TIME OF THIS REPORT
Sore arm for one day now; Itchy rash on upper arm 4 inches by 2 inches; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm for one day now) and RASH PRURITIC (Itchy rash on upper arm 4 inches by 2 inches) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, the patient experienced RASH PRURITIC (Itchy rash on upper arm 4 inches by 2 inches). On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm for one day now). At the time of the report, PAIN IN EXTREMITY (Sore arm for one day now) and RASH PRURITIC (Itchy rash on upper arm 4 inches by 2 inches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.        No relevant concomitant medications were reported. Lab data was not provided.  No treatment information was provided.   Reporter did not allow further contact
was paralyzed for months; awful reactions; Initial information was received on 12-Aug-2021 regarding an unsolicited valid serious case received from a consumer/non-healthcare professional.  This case involves a child (5 or 6 year old) female patient who was paralyzed for months (paralysis) and had awful reaction (adverse reaction) after receiving vaccines DIPHTHERIA, TETANUS AND NOS PERTUSSIS VACCINE and POLIO VACCINE.  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided.   Information of concomitant medications was not reported.  On an unknown date, the patient received a dose of suspect DIPHTHERIA, TETANUS AND NOS PERTUSSIS VACCINE lot number and expiry date: not reported) via unknown route in unknown administration site for prophylactic vaccination. On an unknown date, the patient received a dose of suspect POLIO VACCINE not produced by Sanofi Pasteur (lot number and expiry date: not reported) via unknown route in unknown administration site for prophylactic vaccination. She received the vaccines after birth and at 5 or 6 years old in 1955 or 1956, when she was going into Kindergarten.  On an unknown date, the patient developed a serious event reported as paralyzed for months (paralysis) (unknown latency) following the administration of DIPHTHERIA, TETANUS AND NOS PERTUSSIS VACCINE and POLIO VACCINE. This event was assessed as medically significant.  On an unknown date, the patient developed a non-serious awful reaction (adverse reaction) (unknown latency) following the administration of DIPHTHERIA, TETANUS AND NOS PERTUSSIS VACCINE and POLIO VACCINE.  It was reported the patient had the polio and DIPHTHERIA, TETANUS AND NOS PERTUSSIS VACCINE (DPT) vaccines many years ago and had awful reactions from both and was scared to get the vaccine. She was paralyzed for months at the age of 5 or 6 years old, when she received it going into kindergarten or first grade. The patient's immunologist informed the patient that it was the fourth generation that has had this.  No laboratory data was reported.  It was not reported if the patient received a corrective treatment for the events.  At time of this report, the outcome of the events was unknown.  There will be no information available on batch number for this case.; Sender's Comments: This case concerns a five or six-year-old female patient who was paralysis and had adverse reaction after vaccination DIPHTHERIA, TETANUS AND NOS PERTUSSIS VACCINE (unknown manufacturer) and POLIO VACCINE. The time to onset was unknown. Additional information regarding medical history, condition at the time of vaccination and lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of an individual vaccine cannot be assessed.
Redness; soreness; A spontaneous report was received from a Consumer's wife concerning a 82 years old male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events redness, hardness, and soreness. The patient's medical history includes, he is a  heart patient and on blood thinner.  On 17th JAN 2021 to the onset of the events, the patients received their first of two planned doses of mRNA-1273 intramuscularly in the Anatomical location for prophylaxis of COVID-19 infection. On 18th JAN 2021 , The patient reported the events redness, hardness, and soreness. Treatment Hydrocodone  Action taken with mRNA-1273 in response to the events was not reported. The outcome for the events, redness, hardness, and soreness was not provided
TWO DAYS AFTER RECEIVING IMMUNIZATIONS, INCLUDING ROTATEQ, PRESENTED TO OFFICE WITH BLOODY STOOL
Apparent case of "COVID Arm";  developed a red itchy area roughly 2x4 inch oval at the injection site; onset approximately 7 days after injection; still unresolved but appears to be improving.